Report of Quality Research in Radiation Oncology (QRRO) Survey for Lung Cancer Patients Treated in the USA between 2006 and 2007

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer

“…Response rates were equal (87%), but twice-daily TRT significantly prolonged median OS (23.0 months vs. 19.0 months; p=0.04) [6]. Thus, twice-daily TRT is the most recommended schedule, but not universally adopted [7][8][9][10][11]. Inconvenience of this schedule and concerns about esophagitis are probably the main explanations [10].…”